Navigation Links
Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
Date:10/27/2008

ertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics to Webcast R&D Day on November 12th
2. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
3. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
4. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
5. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
6. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
7. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
10. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... 2011 Dyadic International, Inc. ("Dyadic") (OTC Pink: ... discovery, development, manufacture and sale of enzyme and ... biopharmaceutical industries, today announced financial results for the ... contained in this press release should be read ...
... 2011 SynCo Bio Partners B.V., one of ... its aseptic filling facility is again fully operational and SynCo ... its clients after the expansion of its Class A zone. ... is an important milestone in SynCo,s strategy in supporting its ...
... Gram for gram, novel carbon nanofiber-filled coatings devised by ... (NIST) and Texas A&M University outperformed conventional flame retardants ... mattresses by at least 160 percent and perhaps by ... results, reported in the journal Polymer ,* suggest ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/11/2014)... Bone and Mineral Research awarded Michael F. Holick, PhD, ... the 2014 Louis V. Avioli Award. Holick, a professor ... known for revolutionizing the understanding of vitamin D and ... honors a member of the American Society for Bone ... and mineral basic research. It is named for ASBMR,s ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... Rockies are stifling the mating choices of butterflies in ... and less abundant alpine meadows--largely the result of human ... pattern that could lead to the butterflies being less ... scientist at the University of Alberta and an author ...
... immediate wake of Hurricane Katrina, scientists and research centers ... on the contaminated floodwaters and offer it to hazardous ... matter of hours, the University of North Carolina at ... (RENCI), together with the National Center for Supercomputing Applications ...
... the University of Chicago has developed a non-invasive laboratory technique ... off and on in a living bacterium as it becomes ... The technique, which is announced in the Monday, June 13 ... could help scientists discover new drugs and learn to what ...
Cached Biology News:Expanding forests darken the outlook for butterflies, study shows 2UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina 2UNC computer, marine scientists collaborate to predict flow of toxic waters from Katrina 3Scientists devise way to measure RNA synthesis on the fly in a live cell 2
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
Biology Products: